ALT
BEARISH
$3.5
Live
Altimmune, Inc. · NASDAQ
Target $17.22
(+392.1%)
$2.9
52W Range
$7.73
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$438.31M
P/E
N/A
ROE
-50.6%
Profit margin
N/A
Debt/Equity
0.16
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
ALT exhibits severe financial distress despite strong revenue growth, as evidenced by a Piotroski F-Score of 1/9—indicating poor operational and financial health. The Altman Z-Score is unavailable, but the company's negative profitability metrics (ROE: -50.57%, ROA: -28.17%), massive operating losses, and negative earnings suggest high distress risk. While revenue growth is explosive at 420% YoY, this is not translating into profitability or cash flow, and the stock trades at an extreme Price/Sales of 10,690.50, reflecting speculative valuation. Analysts recommend 'buy' with a $17.22 target, but this is likely driven by pipeline optimism rather than fundamentals. The technical trend is bearish, and insider activity is neutral, offering no conviction.
Key Strengths
420% YoY revenue growth indicates strong top-line momentum
High average earnings surprise (+8.52%) in recent quarters suggests potential for upside in earnings execution
Strong current and quick ratios (18.55 and 18.35) indicate exceptional short-term liquidity
Low debt/equity ratio (0.16) suggests minimal leverage risk
Analyst consensus is 'buy' with a high target price of $17.22, implying strong growth expectations
Key Risks
Piotroski F-Score of 1/9 signals extreme financial weakness and poor operational efficiency
Negative ROE (-50.57%) and ROA (-28.17%) reflect deep unprofitability and capital inefficiency
Operating margin of -111,126.92% indicates massive operational losses relative to revenue
Price/Sales ratio of 10,690.50 is astronomically high, implying extreme overvaluation unless growth is sustained
No free cash flow, operating cash flow, or dividend history—no return to investors
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
24
Weak
15
68
25
10
0
AI Verdict
High risk, speculative
Key drivers: Extremely low Piotroski F-Score (1/9), Negative profitability and cash flow, Unsustainable valuation metrics, High revenue growth without earnings conversion, Lack of dividend or capital return
Confidence
88%
Value
15/100
No reliable valuation metrics exist due to negative earnings; stock trades at a massive premium to sales, likely reflecting speculative growth expectations.
Positives
- Low debt/equity ratio (0.16)
- High current and quick ratios (18.55, 18.35)
Watchpoints
- Price/Sales of 10,690.50 is extreme
- No Graham Number or intrinsic value available
- No P/E or PEG for valuation
- Negative earnings and cash flow
Future
68/100
Future potential is high due to explosive revenue growth and positive earnings surprises, but execution risk is extreme without profitability.
Positives
- 420% YoY revenue growth
- Recent earnings surprises above estimates (avg +8.52%)
- Strong analyst target price ($17.22)
- High analyst coverage (9 analysts)
- Positive momentum in recent quarters
Watchpoints
- No free cash flow or operating cash flow
- Negative earnings growth (Q/Q -28.6%)
- No clear path to profitability
- High burn rate implied by losses
- No guidance or forward metrics
Past
25/100
Past performance shows erratic earnings with periods of extreme underperformance, despite recent improvement in surprise rates.
Positives
- Consistent earnings beat in 2025 and 2026 (2/4 in last 4 quarters)
- Improving earnings trend from -0.81 in 2021 to -0.27 in 2026
- Positive surprises in 2023–2025 (e.g., +30.9%, +28.4%)
Watchpoints
- Historical losses are massive (e.g., -107.7% surprise in 2021)
- Negative earnings in 2020 and 2021 were severe
- No consistent profitability over 25 quarters
- Earnings volatility is extreme
- Most recent Q/Q EPS growth is -28.6%
Health
10/100
Despite strong liquidity, the company's financial health is dire due to persistent losses and poor operational efficiency, as confirmed by the Piotroski F-Score.
Positives
- Low debt/equity (0.16)
- High current and quick ratios (18.55, 18.35)
Watchpoints
- Piotroski F-Score of 1/9 (extremely weak)
- Negative ROE, ROA, and operating margin
- No Altman Z-Score available, but financial distress is evident
- Negative earnings and cash flow
- No signs of financial stability
Dividend
0/100
ALT is a growth-stage biotech with no dividend policy; this is expected but reflects lack of maturity or profitability.
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout
- Payout ratio is 0.00%
- No history of dividend payments
- Company is not a dividend payer
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.5
Analyst Target
$17.22
Upside/Downside
+392.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ALT and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ALT
Altimmune, Inc.
Primary
|
-80.3% | -68.4% | -32.7% | -3.9% | -24.4% | -1.1% |
|
ASMB
Assembly Biosciences, Inc.
Peer
|
-54.7% | +80.2% | +165.0% | +28.7% | +2.8% | -0.6% |
|
PRTC
PureTech Health plc
Peer
|
-68.3% | -33.5% | +9.3% | +1.7% | +12.6% | +10.9% |
|
ACRS
Aclaris Therapeutics, Inc.
Peer
|
-85.2% | -56.5% | +126.9% | +81.5% | +4.4% | +15.7% |
|
XOMA
XOMA Royalty Corporation
Peer
|
+0.5% | +108.7% | +62.3% | +10.6% | +29.7% | -4.3% |
ALT
Altimmune, Inc.
Primary
5Y
-80.3%
3Y
-68.4%
1Y
-32.7%
6M
-3.9%
1M
-24.4%
1W
-1.1%
ASM
Assembly Biosciences, Inc.
Peer
5Y
-54.7%
3Y
+80.2%
1Y
+165.0%
6M
+28.7%
1M
+2.8%
1W
-0.6%
PRT
PureTech Health plc
Peer
5Y
-68.3%
3Y
-33.5%
1Y
+9.3%
6M
+1.7%
1M
+12.6%
1W
+10.9%
ACR
Aclaris Therapeutics, Inc.
Peer
5Y
-85.2%
3Y
-56.5%
1Y
+126.9%
6M
+81.5%
1M
+4.4%
1W
+15.7%
XOM
XOMA Royalty Corporation
Peer
5Y
+0.5%
3Y
+108.7%
1Y
+62.3%
6M
+10.6%
1M
+29.7%
1W
-4.3%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-2.59
PEG Ratio
N/A
P/B Ratio
1.73
P/S Ratio
10690.5
EV/Revenue
5304.32
EV/EBITDA
-2.3
Market Cap
$438.31M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-111127.0%
Gross Margin
N/A
ROE
-50.57%
ROA
-28.17%
Growth
Revenue and earnings growth rates
Revenue Growth
+420.0%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.16
Low debt
Current Ratio
18.55
Strong
Quick Ratio
18.35
Excellent
Cash/Share
$2.1
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-12
$N/A
2026-03-05
$-0.27
-11.2% surprise
2025-11-06
$-0.21
+21.0% surprise
2025-08-12
$-0.27
+15.8% surprise
Healthcare Sector Comparison
Comparing ALT against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-50.57%
This Stock
vs
-88.14%
Sector Avg
-42.6%
(Below Avg)
Debt to Equity
0.16
This Stock
vs
2.66
Sector Avg
-94.0%
(Less Debt)
Revenue Growth
420.0%
This Stock
vs
124.04%
Sector Avg
+238.6%
(Fast Growth)
Current Ratio
18.55
This Stock
vs
4.47
Sector Avg
+314.6%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ALT
Altimmune, Inc.
|
BEARISH | $438.31M | - | -50.6% | -% | $3.5 | |
|
ASMB
Assembly Biosciences, Inc.
|
NEUTRAL | $444.7M | - | -36.9% | -103.6% | $28.11 | Compare |
|
PRTC
PureTech Health plc
|
NEUTRAL | $445.46M | 10.7 | 9.4% | 793.0% | $18.3 | Compare |
|
ACRS
Aclaris Therapeutics, Inc.
|
BEARISH | $428.65M | - | -50.2% | -% | $3.54 | Compare |
|
XOMA
XOMA Royalty Corporation
|
NEUTRAL | $451.49M | 25.95 | 34.1% | 60.8% | $37.89 | Compare |
ALT
Altimmune, Inc.
BEARISH
Mkt Cap
$438M
P/E
-
ROE
-50.6%
Price
$3.5
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-06 | WEAVER GREGORY L | Chief Financial Officer | Purchase | 5,000 | $17,700 |
| 2026-03-06 | DURSO JEROME BENEDICT | Chief Executive Officer | Purchase | 20,000 | $70,790 |
| 2026-02-02 | ROBERTS M SCOT | Officer | Stock Award | 17,050 | - |
| 2026-01-30 | JORDT RAYMOND M | Officer | Stock Award | 4,571 | $25,598 |
| 2026-01-30 | ROBERTS M SCOT | Officer | Stock Award | 5,567 | $31,175 |
| 2026-01-30 | GARG VIPIN K. | Director | Stock Award | 6,926 | $38,786 |
| 2026-01-30 | GARG VIPIN K. | Director | Stock Award | 26,775 | - |
| 2026-01-27 | GARG VIPIN K. | Director | Stock Award | 41,200 | - |
| 2026-01-27 | JORDT RAYMOND M | Officer | Stock Award | 15,850 | - |
| 2026-01-23 | ROBERTS M SCOT | Officer | Stock Award | 14,600 | - |
| 2026-01-23 | GARG VIPIN K. | Director | Stock Award | 42,050 | - |
| 2026-01-23 | JORDT RAYMOND M | Officer | Stock Award | 14,600 | - |
| 2026-01-08 | PISANO WAYNE | Director | Purchase | 5,000 | $20,410 |
| 2026-01-05 | SOHN CATHERINE A | Director | Purchase | 500 | $1,755 |
| 2025-12-31 | JORDT RAYMOND M | Officer | Stock Award | 9,375 | - |
WEAVER GREGORY L
Chief Financial Officer
2026-03-06
5,000 shares
·
$17,700
DURSO JEROME BENEDICT
Chief Executive Officer
2026-03-06
20,000 shares
·
$70,790
ROBERTS M SCOT
Officer
2026-02-02
17,050 shares
JORDT RAYMOND M
Officer
2026-01-30
4,571 shares
·
$25,598
ROBERTS M SCOT
Officer
2026-01-30
5,567 shares
·
$31,175
GARG VIPIN K.
Director
2026-01-30
6,926 shares
·
$38,786
GARG VIPIN K.
Director
2026-01-30
26,775 shares
GARG VIPIN K.
Director
2026-01-27
41,200 shares
JORDT RAYMOND M
Officer
2026-01-27
15,850 shares
ROBERTS M SCOT
Officer
2026-01-23
14,600 shares
GARG VIPIN K.
Director
2026-01-23
42,050 shares
JORDT RAYMOND M
Officer
2026-01-23
14,600 shares
PISANO WAYNE
Director
2026-01-08
5,000 shares
·
$20,410
SOHN CATHERINE A
Director
2026-01-05
500 shares
·
$1,755
JORDT RAYMOND M
Officer
2025-12-31
9,375 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
9 analysts
B. Riley Securities
2026-03-06
Buy
Buy
Citizens
2025-11-07
Market Outperform
Market Outperform
HC Wainwright & Co.
2025-10-20
Buy
Buy
HC Wainwright & Co.
2025-10-10
Buy
Buy
Past News Coverage
Recent headlines mentioning ALT from our newsroom.
Newest → oldest
No matching news yet.